Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies

OBJECTIVE: Depressive symptoms are common in schizophrenia and can worsen outcomes and increase suicide risk. Lurasidone is an atypical antipsychotic agent indicated for the treatment of schizophrenia and for the treatment of major depressive episodes associated with bipolar I disorder. This post ho...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:CNS Spectr
Autors principals: Nasrallah, Henry A., Cucchiaro, Josephine B., Mao, Yongcai, Pikalov, Andrei A., Loebel, Antony D.
Format: Artigo
Idioma:Inglês
Publicat: Cambridge University Press 2014
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4411643/
https://ncbi.nlm.nih.gov/pubmed/24955752
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1017/S1092852914000285
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars